PIPELINES

 

Antapodia 03 (AP-03)

AP-03 is Antapodia Biotherapeutic's another invadopodia-targeted mAb that can specifically block the ability of MIR-03 to activate matrix metalloproteinases (MMPs), thereby inhibiting the proteolytic function of invadopodia and cancer cell invasion (Figure 1). Antapodia has conducted compelling PoM and PoC studies in preclinical models showing that systemic administrations of AP-03 could effectively inhibit the distant metastases of pancreatic cancer (Figure 2) and the dissemination of non-small cell lung cancer (Figure 3). The company is conducting PDX tumor models to further verify the therapeutic potential of AP-03.

Figure 1.  AP-03 inhibits the invasive capacity of PDAC and NSCLC cells

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival(metastasis control rate = 79.4%; survival extension = 28%).

PDAC: pancreatic ductal adenocarcinoma; NSCLC: non-small cell lung cancer.

Figure 2. Systemic AP-03 therapy attenuates the distant metastasis of PDAC and extends survival

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival(metastasis control rate = 79.4%; survival extension = 28%).

PDAC: pancreatic ductal adenocarcinoma; NSCLC: non-small cell lung cancer. Red arrows indicate the time of AP-03 injections. Note that all the mice treated with control IgG died before 6 weeks follwoing initiation of the treatments.

Figure 3.  Systemic AP-03 therapy attenuates the dissemination of NSCLC and extends survival

Figure 1.  Systemic administration of AP-01 attenuates PDAC metastasis and lengthens survival(metastasis control rate = 79.4%; survival extension = 28%).
Copyright © Antapodia Biotherapeutics, Inc. All Rights Reserved

Search